Top Page
Shanghai Henlius Biotech, Inc. Class H
(2696)
Shanghai Henlius Biotech, Inc. Class H (2696) vs. iShares MSCI Hong Kong ETF (EWH)
Shanghai Henlius Biotech, Inc. Class H Business Overview & Revenue Model
Shanghai Henlius Biotech, Inc. Class H Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 5.72B | 5.39B | 3.21B | 1.68B | 587.59M |
| Gross Profit | 4.18B | 3.92B | 2.37B | 1.16B | 405.47M |
| EBITDA | 1.15B | 911.33M | -310.61M | -671.74M | -814.06M |
| Net Income | 820.47M | 546.02M | -695.26M | -984.05M | -1.04B |
Balance Sheet | |||||
| Total Assets | 10.60B | 9.90B | 8.92B | 7.17B | 6.44B |
| Cash, Cash Equivalents and Short-Term Investments | 772.96M | 1.01B | 833.66M | 154.98M | 1.11B |
| Total Debt | 3.65B | 4.09B | 3.68B | 2.62B | 1.83B |
| Total Liabilities | 7.58B | 7.71B | 7.29B | 4.88B | 3.24B |
| Stockholders Equity | 3.01B | 2.19B | 1.64B | 2.30B | 3.20B |
Cash Flow | |||||
| Free Cash Flow | 404.68M | 36.48M | -383.67M | -1.04B | -2.12B |
| Operating Cash Flow | 1.24B | 1.05B | 981.62M | 90.39M | -609.58M |
| Investing Cash Flow | -909.97M | -1.00B | -1.36B | -1.68B | -1.51B |
| Financing Cash Flow | -643.37M | 144.43M | 858.02M | 648.30M | 995.79M |
Shanghai Henlius Biotech, Inc. Class H Technical Analysis
Shanghai Henlius Biotech, Inc. Class H Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | HK$40.35B | 45.36 | 31.65% | ― | 4.23% | 47.71% | |
51 Neutral | $7.27B | -0.06 | -62.84% | 2.34% | 15.16% | -2.86% | |
| ― | €3.30B | ― | -29.51% | ― | ― | ― | |
61 Neutral | HK$26.07B | ― | -6.35% | ― | 33.63% | 31.50% | |
54 Neutral | HK$42.33B | ― | -19.78% | ― | 25.96% | 39.58% | |
| ― | HK$30.46B | 38.92 | 10.27% | 1.42% | ― | ― | |
48 Neutral | HK$30.45B | ― | -253.12% | ― | 330.23% | 59.68% |
Shanghai Henlius Biotech, Inc. Class H Corporate Events
Shanghai Henlius Biotech, Inc. has announced a board meeting scheduled for August 25, 2025, to review and approve the interim results for the first half of 2025 and to discuss the potential payment of an interim dividend. This meeting could influence the company’s financial strategy and shareholder returns, potentially impacting its market position and investor relations.
The most recent analyst rating on (HK:2696) stock is a Buy with a HK$61.98 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.
Shanghai Henlius Biotech, Inc. announced that its biosimilar drug HLX14, a recombinant anti-RANKL human monoclonal antibody injection, has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). This recommendation for approval is a significant step towards gaining centralized marketing authorization across the EU and EEA countries. The positive opinion is based on data demonstrating analytical similarity and clinical efficacy compared to the reference drug, denosumab. This development positions Henlius as a competitive player in the global biosimilar market, with potential implications for stakeholders as the drug progresses towards final approval.
The most recent analyst rating on (HK:2696) stock is a Buy with a HK$61.98 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.
Shanghai Henlius Biotech, Inc. held its 2025 second extraordinary general meeting where several resolutions were passed. These included the approval of a Share Option Scheme and an RSU Scheme, both receiving overwhelming support from shareholders. The meeting was conducted in compliance with relevant laws and regulations, and the resolutions are expected to enhance the company’s operational flexibility and incentivize service providers, potentially strengthening its market position.
The most recent analyst rating on (HK:2696) stock is a Buy with a HK$61.98 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.
Shanghai Henlius Biotech, Inc. has announced the dosing of the first patient in the United States for its international multi-center phase 3 clinical study of HLX22, a recombinant humanized anti-HER2 monoclonal antibody, in combination with Trastuzumab and chemotherapy for the treatment of HER2-positive gastroesophageal junction and gastric cancer. This study, which is also being conducted in China, Australia, Japan, and other regions, aims to evaluate the efficacy and safety of HLX22, potentially enhancing the company’s position in the oncology market by addressing critical unmet needs in cancer treatment.
The most recent analyst rating on (HK:2696) stock is a Buy with a HK$61.98 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.
Shanghai Henlius Biotech, Inc. has announced an extraordinary general meeting to be held on July 21, 2025, to consider and approve several resolutions related to its Share Option Scheme and RSU Scheme. These resolutions include authorizing the issuance of shares and granting RSUs, which could impact the company’s operational flexibility and stakeholder interests.
The most recent analyst rating on (HK:2696) stock is a Buy with a HK$61.98 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.
Shanghai Henlius Biotech, Inc. announced that its subsidiary, Henlius Biologics, has received EU GMP certification for its production lines of HLX11 and HLX14, indicating compliance with European manufacturing standards. This certification enhances the company’s industry positioning by facilitating the global commercialization of its biosimilar products, potentially impacting stakeholders by expanding market access and increasing competitiveness in the pharmaceutical industry.
The most recent analyst rating on (HK:2696) stock is a Buy with a HK$61.98 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.
Shanghai Henlius Biotech, Inc. has entered into a license agreement with FBD Biologics Limited for the exclusive rights to develop, manufacture, and commercialize the fusion protein HCB101 in specified territories including Mainland China, Hong Kong, Macao, Southeast Asia, and parts of the MENA region. This strategic partnership allows Henlius to advance its oncology pipeline with HCB101, currently in phase 1b/2a clinical trials, potentially enhancing its market positioning and offering significant growth opportunities in the biopharmaceutical sector.
The most recent analyst rating on (HK:2696) stock is a Buy with a HK$61.98 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.
Shanghai Henlius Biotech, Inc. has announced the proposed adoption of a Share Option Scheme and an RSU Scheme, aimed at attracting and retaining skilled personnel to drive the company’s long-term development goals. The schemes, subject to shareholder approval, are designed to align the interests of participants with shareholders through share ownership, and include conditional grants to key personnel, such as Dr. Zhu, to enhance the company’s value and stakeholder benefits.
The most recent analyst rating on (HK:2696) stock is a Buy with a HK$61.98 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.
Shanghai Henlius Biotech, Inc. has announced proposed amendments to its Articles of Association and other corporate governance measures to align with updated legal and regulatory requirements. Additionally, the company has appointed new members to its Nomination Committee, enhancing its governance structure in accordance with revised listing rules.
The most recent analyst rating on (HK:2696) stock is a Buy with a HK$61.98 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.
Shanghai Henlius Biotech, Inc. has announced amendments to the terms of reference for its Nomination Committee, initially established in 2019. The changes emphasize the inclusion of independent non-executive directors and gender diversity within the committee, reflecting the company’s commitment to robust governance and inclusive leadership practices.
The most recent analyst rating on (HK:2696) stock is a Buy with a HK$61.98 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.
Shanghai Henlius Biotech, Inc. has announced the composition of its board of directors, highlighting the roles and functions of each member. This announcement is crucial for stakeholders as it outlines the governance structure and strategic oversight, potentially impacting the company’s future direction and market positioning.
The most recent analyst rating on (HK:2696) stock is a Buy with a HK$61.98 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.
Shanghai Henlius Biotech, Inc. announced the dosing of the first patient in a bridging study in Japan for HANSIZHUANG, combined with chemotherapy, targeting extensive-stage small cell lung cancer. This study aims to support the future marketing application of HANSIZHUANG in Japan, following successful international trials. The company is advancing multiple clinical studies globally, enhancing its position in the oncology market.
Shanghai Henlius Biotech, Inc. has announced the dosing of the first patient in an international multicentre phase 2 clinical study of HLX43, an anti-PD-L1 antibody-drug conjugate, for advanced non-small cell lung cancer in mainland China. This study aims to evaluate the efficacy and safety of HLX43, with the primary endpoint being the objective response rate. The phase 1 clinical trial results showed promising safety profiles and anti-tumor activity, particularly in non-small cell lung cancer and thymic squamous cell carcinoma, indicating potential positive implications for the company’s market positioning and stakeholders.
Shanghai Henlius Biotech, Inc. has announced that the China Securities Regulatory Commission (CSRC) has accepted its application for the H Share Full Circulation. This development will allow certain unlisted shares of the company to be converted into H shares, which will be listed and traded on the Main Board of the Hong Kong Stock Exchange. This move is expected to enhance the company’s market presence and liquidity, providing more opportunities for investors and potentially strengthening its position in the biopharmaceutical industry.
Shanghai Henlius Biotech, Inc. announced that its subsidiary, Henlius Europe GmbH, received orphan-drug designation from the European Commission for HLX22, a recombinant humanized anti-HER2 monoclonal antibody injection, for the treatment of gastric cancer. This designation, which follows a positive opinion from the European Medicines Agency, highlights the company’s progress in developing HLX22, which is undergoing various clinical trials for different cancer indications. The global market for HER2-targeting monoclonal antibody products was valued at approximately $9.029 billion in 2024, indicating significant market potential for HLX22.
Shanghai Henlius Biotech, Inc. announced the dosing of the first patient in a Phase 1/3 clinical study of its Ipilimumab biosimilar, HLX13, for the treatment of unresectable advanced hepatocellular carcinoma in mainland China. This trial aims to assess the pharmacokinetic profiles, efficacy, safety, and immunogenicity of HLX13 compared to its reference product, YERVOY. The study’s successful progression could enhance the company’s market position in the oncology biosimilar sector, potentially impacting stakeholders positively by expanding treatment options for various cancers.
Shanghai Henlius Biotech, Inc. has been included in the MSCI Global Small Cap Indexes, effective after the market close on May 30, 2025. This inclusion is significant as the MSCI Indexes are widely referenced by international investment institutions, potentially enhancing the company’s visibility and attractiveness to investors.
Shanghai Henlius Biotech, Inc. successfully held its Annual General Meeting (AGM) on May 8, 2025, where all proposed resolutions were passed with significant shareholder support. The resolutions included the approval of the company’s annual report, board work report, board of supervisors’ work report, and final accounts report for the year 2024, reflecting strong operational performance and governance.